Author:
Liu Yanxia,Liu Jie,Zhang Shouwei,Wang Jinyue,Sun Zhihong,Sun Huaibo,Yang Ying,Zheng Guangmin,Huang Yu,Li Meng,Zhang Zhaojun,Xiao Jingfa,Zeng Changqing,Sun Chengming,Qu Hongzhu,Fang Xiangdong
Abstract
AbstractCirculating cell-free DNA (cfDNA) in the peripheral blood is a promising biomarker for cancer diagnosis and prognosis. Somatic mutations identified in cancers have been used to detect therapeutic targets for clinical transformation and individualize drug selection, while germline variants can predict a patient’s risk of developing cancer and drug sensitivity. However, no platform has been developed to analyze, calculate, integrate, and friendly visualize these pan-cancer cfDNA mutations deeply. In this work, we performed panel sequencing encompassing 1,115 cancer-related genes across 16,659 cancer patients, spanning 27 cancer types. We detected 496 germline variants in leukocytes and 11,232 somatic mutations in the cfDNA of all patients. CPGV (Cancer Peripheral blood Gene Variations), a database constructed from this dataset, is the first pan-cancer cfDNA database that encompasses somatic mutations, germline variants, and further comparative analyses of mutations across different cancer types. It bears great promise to serve as a valuable resource for cancer research.
Publisher
Springer Science and Business Media LLC